• Global DNA methylation analysis reveals significant DMRs comparing WM with IgM-MGUS and IgM gammopathies with controls across genomic regions.

  • Epigenetic influence on cellular pathways, including cell signaling and inflammatory response pathways, was observed.

Abstract

Currently, the role of DNA methylation in the immunoglobulin M (IgM) monoclonal gammopathy disease spectrum remains poorly understood. In the present study, a multiomics prospective analysis was conducted integrating DNA methylation, RNA sequencing (RNA-seq), and whole-exome sequencing data in 34 subjects (23 with Waldenström macroglobulinemia [WM], 6 with IgM monoclonal gammopathy of undetermined significance [MGUS], and 5 normal controls). Analysis was focused on defining differences between IgM gammopathies (WM/IgM-MGUS) compared with controls, and specifically between WM and IgM-MGUS. Between groups, genome-wide DNA methylation analysis demonstrated a significant number of differentially methylated regions that were annotated according to genomic region. Next, integration of RNA-seq data was performed to identify potentially epigenetically deregulated pathways. We found that pathways involved in cell cycle, metabolism, cytokine/immune signaling, cytoskeleton, tumor microenvironment, and intracellular signaling were differentially activated and potentially epigenetically regulated. Importantly, there was a positive enrichment of the CXCR4 signaling pathway along with several interleukin (interleukin 6 [IL-6], IL-8, and IL-15) signaling pathways in WM compared with IgM-MGUS. Further assessment of known tumor suppressor genes and oncogenes uncovered differential promoter methylation of several targets with concordant change in gene expression, including CCND1 and CD79B. Overall, this report defines how aberrant DNA methylation in IgM gammopathies may play a critical role in the epigenetic control of oncogenesis and key cellular functions.

1.
Gertz
MA
.
Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
.
Am J Hematol
.
2023
;
98
(
2
):
348
-
358
.
2.
Lakshminarasimhan
R
,
Liang
G
.
The role of DNA methylation in cancer
.
Adv Exp Med Biol
.
2016
;
945
:
151
-
172
.
3.
Guillamot
M
,
Cimmino
L
,
Aifantis
I
.
The impact of DNA methylation in hematopoietic malignancies
.
Trends Cancer
.
2016
;
2
(
2
):
70
-
83
.
4.
Mondello
P
,
Paludo
J
,
Novak
JP
, et al
.
Molecular clusters and tumor-immune drivers of IgM monoclonal gammopathies
.
Clin Cancer Res
.
2023
;
29
(
5
):
957
-
970
.
5.
Hodge
LS
,
Ansell
SM
.
Jak/Stat pathway in Waldenstrom's macroglobulinemia
.
Clin Lymphoma Myeloma Leuk
.
2011
;
11
(
1
):
112
-
114
.
6.
Elsawa
SF
,
Ansell
SM
.
Cytokines in the microenvironment of Waldenstrom's macroglobulinemia
.
Clin Lymphoma Myeloma
.
2009
;
9
(
1
):
43
-
45
.
7.
Leleu
X
,
Jia
X
,
Runnels
J
, et al
.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
.
Blood
.
2007
;
110
(
13
):
4417
-
4426
.
8.
Kaiser
LM
,
Hunter
ZR
,
Treon
SP
,
Buske
C
.
CXCR4 in Waldenstrom's macroglobulinema: chances and challenges
.
Leukemia
.
2021
;
35
(
2
):
333
-
345
.
9.
Chohan
K
,
Paludo
J
,
Dasari
S
, et al
.
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis
.
Haematologica
.
2024
;
109
(
5
):
1570
-
1575
.
10.
Bailey
MH
,
Tokheim
C
,
Porta-Pardo
E
, et al
.
Comprehensive characterization of cancer driver genes and mutations
.
Cell
.
2018
;
173
(
2
):
371
-
385.e18
.
11.
Montalto
FI
,
De Amicis
F
.
Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma
.
Cells
.
2020
;
9
(
12
):
2648
.
12.
Jimenez
C
,
Alonso-Alvarez
S
,
Alcoceba
M
, et al
.
From Waldenstrom's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation
.
Blood Cancer J
.
2017
;
7
(
8
):
e591
.
13.
Rosenthal
AC
,
Munoz
JL
,
Villasboas
JC
.
Clinical advances in epigenetic therapies for lymphoma
.
Clin Epigenetics
.
2023
;
15
(
1
):
39
.
You do not currently have access to this content.
Sign in via your Institution